Primary Sjögren's syndrome: time for prospective cohorts.
Many important clinical questions concerning primary Sjögren's syndrome (pSS) remain, that can only be adequately addressed by prospective cohorts. Thus, a better knowledge of the clinical outcome, the course of disease activity and the risk factors of lymphoma requires the setting up of cohorts with biobanks. The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers. Three large prospective cohorts have already started to enroll patients with pSS. This will be highly invaluable for scientists and clinicians to gain a better insight into the pathogenesis of pSS, as well as to identify prognostic markers and new therapeutic targets.
Service de Rhumatologie, Centre National de Reference pour les Maladies Auto-Immunes Systemiques Rares, Hopitaux Universitaires de Strasbourg, EA 4438, Physiopathologie des Arthrites, Universite de Strasbourg, France. jacques-eric.gottenberg@chru-strasbourg.fr
Jacques-Eric
JE
Gottenberg
Xavier
X
Mariette
D015415:Biomarkers; D015331:Cohort Studies; D005602:France; D006801:Humans; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D012859:Sjogren's Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D006113:United Kingdom
D015415:Biomarkers